Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck

1794 - Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of Cabazitaxel versus docetaxel in recurrent Head and Neck Cancer (337O)

Date

18 Nov 2017

Session

Head and neck

Presenters

VIKAS TALREJA

Citation

Annals of Oncology (2017) 28 (suppl_10): x100-x110. 10.1093/annonc/mdx665

Authors

V.T. TALREJA1, V. Patil2, A. Joshi1, V. Noronha3, A. Chandrasekharan1, S. Dhumal1, N. Pande1, S. Turkar1, S. Shrirangwar1, A. Mahajan4, S. Juvrekar1, A. Bhattacharjee5, K. Prabhash3

Author affiliations

  • 1 Medical Oncology, TATA MEMEORIAL HOSPITAL, 400012 - mumbai/IN
  • 2 Medical Oncology, Tata Memorial Hospital Centre, 400068 - Mumbai/IN
  • 3 Medical Oncology, Tata Memorial Hospital Centre, 400012 - Mumbai/IN
  • 4 Radiodiagnosis, Tata Memorial Hospital Centre, 400012 - Mumbai/IN
  • 5 Biostatistics, Tata Memorial Hospital Centre, 400012 - Mumbai/IN
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1794

Background

This analysis was done with the aim to study the overall impact of docetaxel and cabazitaxel treatment by using quality of life without toxicity or symptoms (QTWiST) analysis in head and neck cancer patients receiving second line treatment

Methods

OS (Overall survival) was partitioned in three health states for QTWiST analysis.TOX state was defined as the cumulative number of days spent in grade 3 or above toxicity post randomization and before progression.TWiST state was defined as the cumulative number of days spent post randomization and before progression without grade 3 or above toxicity. REL state was defined as the time spent in days post progression till death. A threshold utility analysis was performed. The difference in mean QTWiST scores with its 95% CI and corresponding p value between the 2 arms was calculated.

Results

The restricted mean TOX state duration in cabazitaxel arm was 2.26 days (95%CI 1.12-3.40) versus 1.543 days (95% CI 0.56-2.53 days) in docetaxel arm. In threshold utility analysis the mean difference in QTWiST was in favour of docetaxel arm and ranged from -7.194 (utility for TOX to -35.96. For any combination of utility score of REL > 0, with any combination of utility score of TOX the difference in mean QTWiST between the 2 arms was greater than 14 days (ie > 10% of OS), in favour of docetaxel arm which is considered clinically meaningful.

Conclusions

Patient randomised to docetaxel arm have higher QTWiST score than patients in cabazitaxel arm and the differences are clinically meaningful in any combination of utility score of TOX with a utility score of REL > 0.

Clinical trial identification

Legal entity responsible for the study

Tata Memorial Hospital

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.